Kansai Paint's Q3 Financial ResultsFinancial statementsKansai Paint's Q3 2025 report reveals a 5.3% sales increase to ￥444.75 billion but a 39% drop in net profit. The company revises full-year guidance, citing economic challenges in key markets like India, Europe, and Asia.
Novo Nordisk 2024 Annual ReportFinancial statementsNovo Nordisk's 2024 annual report highlights strong growth, with total revenue reaching $42.13 billion. Key drivers include semaglutide sales, insulin growth, and efficient product development in diabetes, obesity, and rare diseases care.
PPG's 2024 RevenueFinancial statementsPPG's 2024 revenue dropped by 2% to $15.845 billion, impacted by sales volume and exchange rates. However, sales in China, aerospace, and other regions saw growth. The company anticipates moderate organic sales growth in 2025 despite macro challenges.
AkzoNobel's 2024 RevenueFinancial statementsAkzoNobel's 2024 financial results show stable revenue of $11.62 billion, with a 23% rise in net profit to $588 million. Key highlights include growth in coatings, especially in ship and powder coatings, despite challenges in China.
Amgen 2024 Q4 Financial ReportFinancial statementsAmgen reports strong 2024 earnings but faces a setback as the FDA halts its obesity drug AMG 513. Despite this, progress continues with other promising weight loss candidates like MariTide.
Roche 2024 Financial ReportFinancial statementsRoche's 2024 financial report reveals a 7% revenue growth, driven by strong sales of ophthalmology drug Vabysmo and a solid performance in China. Key therapeutic areas like oncology and neurology continue to show growth.
Takeda 2024 Q3 Financial ReportFinancial statementsTakeda’s 2024 financial report shows a $290M revenue for Fuquatinib and strong growth across its key segments. The company also announces CEO succession with Julie Kim to succeed Christophe Weber in 2026.
Novartis 2024 Q4 Financial ReportFinancial statementsNovartis' 2024 financial report highlights strong growth with key products like Entresto, Cosentyx, and Pluvicto. The company saw a 12% revenue increase, with China market sales up 21%. Strong prospects include new treatments and strategic acquisitions.
AbbVie 2024 Q4 Financial ReportFinancial statementsAbbVie’s 2024 financial report reveals strong growth with Skyrizi surpassing $10 billion in revenue, offsetting the decline of Humira. The company expects continued growth with new immunology deals and pipeline advancements.
Enhertu Sales Report 2024Financial statementsDaiichi Sankyo's Enhertu achieved $3.4B in 2024 sales, a 52% YoY increase. The company also reports strong growth in HER2-positive breast cancer treatment and expanded indications in China and the U.S.
